Download our whitepaper,

Unlocking Success in
Hypercholesterolemia Trials:
Epidemiology, Endpoints, and
Optimized Trial Design​

What's Inside:

  • Key FDA-Approved Pivotal Endpoints for Hypercholesterolemia Clinical Trials.
  • Optimizing Recruitment with Adaptive Trial Designs for Hypercholesterolemia.
  • Comprehensive Analysis of FDA-Approved Hypercholesterolemia Drugs.
  • How Diagnostic Criteria for Hypercholesterolemia Have Evolved and Impact Research.
  • Overcoming Common Pitfalls in Hypercholesterolemia Clinical Trials.
  • And additional insights to drive your trial’s success.

Access your complimentary whitepaper today:






    Hypercholesterolemia

    Hypercholesterolemia, marked by elevated cholesterol levels, is a significant contributor to cardiovascular disease, the leading global cause of death.

    Despite advancements in treatment, the complexity of the condition underscores the need for continued innovation in clinical trials to develop effective therapies and refine protocols.

    This whitepaper explores the critical aspects of hypercholesterolemia clinical trials, including diagnostic criteria, epidemiology, pivotal endpoints, and the challenges of endpoint determination. It also examines FDA-approved therapies, failed drug candidates, and common pitfalls in trial design, highlighting lessons from past failures. Safety concerns, a key consideration in lipid-lowering therapies, are addressed with strategies for risk mitigation.

    iNGENū’s team of researchers and clinicians is dedicated to advancing hypercholesterolemia research. Through innovative trial designs and a patient-centered approach, we work to accelerate the development of new treatments that could offer improved options and outcomes for those affected by hypercholesterolemia.

    85%

    of people are undiagnosed, leaving them at higher cardiovascular risk

    99%

    of individuals with hypercholesterolemia have genetic or lifestyle-related causes

    1 in 5

    adults in the U.S. has high total cholesterol levels

    Our clinical team has over

    120

    years of combined clinical trial experience